The city of Jiaxing, in the eastern region of China, offers some inhabitants a vaccine experimental against coronavirus at $ 60, local officials announced, the first such operation in the country, which takes place with a vaccine that has not yet been approved.
Residents aged 18 to 59 and in “urgent” situations can go to the hospital for possible administration of the vaccine by the private company Sinovac Biotech, which the authorities have already applied in groups such as health professionals.
The Jiaxing center for disease control and prevention has not explained what is considered an “urgent” situation.
Authorities did not say how many people in the city had received the vaccine, given in two doses administered up to 28 two intervals and at a total cost of 400 yuan ($ 59).
At the same time, China has administered an experimental vaccine to hundreds of thousands of workers in areas considered essential, in ports, hospitals and other high-risk sectors across the country, according to authorities.
Although 11 vaccines originating in this country have started clinical trials – four of them in advanced phase three tests, including Sinovac’s -, none has been approved for commercialization.
China is trying to win the global race for a vaccine against a virus that emerged in the city of Wuhan and, at the same time, is trying to convey an image of recovery in the health situation and the economic crisis.
The government has approved some vaccine candidates for emergency use, with the assurance that no serious adverse reactions have been reported.
Health officials announced last month that the country expects to be able to produce 610 million doses by the end of the year and that they would be affordable.